Resource Tycoon Reborn

"China's pharmaceutical industry opened up to the outside world earlier. As early as the 1980s, foreign-funded pharmaceutical companies have settled in the mainland. Over the years, global multinational pharmaceutical companies have continued to expand their investment in China, and competition is relatively sufficient. And according to China

According to the WTO agreement signed by the government, China's pharmaceutical distribution field will be fully opened to the outside world from December 11 this year. Foreign companies can engage in all business activities in China, including procurement, warehousing, transportation, retail and after-sales services. Therefore,

Many foreign pharmaceutical companies have not only established new R&D centers in China, but have also extended their tentacles to other areas of pharmaceuticals. According to my statistics, the top 20 pharmaceutical companies in the world include Roche, Novartis, Bayer, Merck, etc.

Enterprises have now invested and set up factories in China to compete in the Chinese pharmaceutical market." Angelina had obviously made full preparations in advance, and she had a wealth of data about the Chinese pharmaceutical market.

"Although this market is an attractive big cake, I think we have missed the opportunity to enter. If ten years ago, our Welf family could merge and reorganize these seven pharmaceutical companies into a large pharmaceutical company

If we become a group company and advance into the Chinese pharmaceutical market, we will be one of the people sharing the cake today." Angelina said.

"Angelina, there is no need to say this in the future. The focus of family business has never been on the pharmaceutical industry. I think you are also very clear about this." Old Welf interjected, "And in the future, if

Even if there are no particularly good opportunities, family capital will still not enter the pharmaceutical industry on a large scale. Of course, eggs cannot be put in one basket, but they cannot be put in every basket."

"Yes!" Angelina bowed her head and said, "The focus of the family business is not on the pharmaceutical industry, and the market of these seven pharmaceutical companies is mainly in the European market, and the share of overseas markets can be said to be very small.

. Therefore, I think that transferring these drug patents to the Fang family and restricting them to production and sales in China will have a minimal impact on the family's seven pharmaceutical companies. But for our acquisition of the equity of Haiping Mining Company, it will

It plays a vital role!”

"But the result of doing this is likely to anger other pharmaceutical companies." Lewis said.

"So what if we are angry? The worst result is that we withdraw from the pharmaceutical industry, but when did we really enter the pharmaceutical industry?" Angelina asked, "If it is other industries, we Welf

When has the family ever been afraid of competition?”

"Bah bang bang..." Old Welf applauded, "Angelina, you said it well. In other industries, if we can't even bear the anger of these pharmaceutical companies, then these companies will come again.

What’s the use?”

"Dad, what I mean is, will the families who control those pharmaceutical companies have any objections to us?" Louis was almost speechless. Of course, you can ignore the anger of pharmaceutical companies, but what is behind any successful multinational company?

Isn’t there one or a few wealthy families? And these families often span several industries.

"Compared with the possible profits in the future, their opinions are not worthy of our concern!" Angelina said loudly, "If we have to consider their opinions in everything we do, then unless it is an emerging industry, which industry

Let’s all stay out of it.”

"In the emerging industry, do we, the Welf family, have no rivals? They don't care whether we have any opinions or not." Old Welf said calmly. Louis' face turned red.

"So, I think it is very worthwhile to give up the Chinese pharmaceutical market, which is almost non-existent for our family, in exchange for the opportunity to obtain the equity of Haiping Mining Company!" Angelina said. "If we miss this opportunity,

Maybe we need to give something more in exchange."

On the highway back to the ancient city of Pingchuan, Fang Mingyuan was carefully looking through the information in his hands, exchanging opinions with Zheng Jiayi on the side from time to time.

"Mingyuan. Do you think Chief Welf will agree to your proposal?" Zheng Jiayi said a little uneasily. She only found out at noon yesterday that Fang Mingyuan actually made a request to the Welf family to obtain the Welf family's medicine.

The drug patent rights owned by the company. Her first reaction at that time was that Fang Mingyuan had dug another big hole silently! The Fang family can be said to have no foundation in the pharmaceutical industry, and

Before, Fang Mingyuan had not revealed the slightest hint. If there was any connection, it would be the hospitals in Tongyi, whether they are municipal or joint ventures, the Fang family had a hand in them.

.

"Don't worry, old Welf will definitely agree!" Fang Mingyuan said without raising his head. Angelina has already made the Welf family's attitude towards these pharmaceutical companies very clear.

More than half of this information was provided by Angelina. For the Welf family, it was just a useless industry, and Fang Mingyuan did not want the ownership of those companies, but only wanted the drug patents in their hands.

China's manufacturing and sales rights are exchanged for the opportunity to acquire the equity of Haiping Mining Company. This kind of advantage has no harm to the Welf family at all. It would be strange for old Welf not to take advantage of it.

"But... I still feel that we have lost money." Zheng Jiayi said. After transferring the equity of Haiping Mining Company, which has full profits, what it got back was only some drug patents with uncertain prospects. The Fang family still needs to make large investments, and even

Since it may take several years to make a profit, this doesn't seem like a good deal, and it also means that Fang Mingyuan's workload will increase again.

"It's not a loss, I plan to use them to make a deal with the country." Fang Mingyuan said calmly, "Don't tell anyone." Of course he understood how deep the troubled waters of the domestic pharmaceutical market are, even if the Fang family

, if you enter recklessly, you may have to be mentally prepared to suffer losses for many years. However, this does not mean that these drug patents cannot be used!

"Ah?" Zheng Jiayi was startled for a moment, and then suddenly realized, her pretty face immediately became more radiant. Yes, why did she get into trouble? She just thought about how much more investment the Fang family would have to do after getting the patent rights for these drugs.

, but did not expect that these drug patents could be resold in exchange for what the Fang family needed.

"Huh..." Fang Mingyuan let out a long breath and raised his head. Before meeting old Welf, he read all the information again.

From the beginning, he had no intention of letting the Fang family enter the pharmaceutical field, but planned to use these drug patents in exchange for other things from the country. In today's Chinese pharmaceutical industry, the market share of foreign-funded and private-owned enterprises is gradually increasing.

Expanding, the growth rate is still accelerating. In the 2000s, state-owned pharmaceutical companies were still able to occupy more than 60% of the domestic pharmaceutical market. With the full opening of the pharmaceutical circulation field to the outside world in December this year

, it is conceivable that those foreign-funded enterprises will definitely acquire domestic counterparts on a large scale by then, so as to avoid policy and regulatory obstacles, save entry costs, and expand their market share through the original marketing channels of these enterprises.

Although these domestic pharmaceutical companies are numerous in number, most of them do not master core technologies and brands. Their products are mainly generic drugs. As a result, they are widely used in domestic hospitals, pharmacies, community hospitals, rural clinics and other medical and health terminals at all levels.

The market is flooded with a large number of generic drugs produced by different companies with the same efficacy, but there are very few self-developed drugs with patent rights.

Since the 1990s, China has signed intellectual property protection agreements with the United States, the European Union, Japan and other countries. After joining the WTO, it has to fully implement intellectual property protection. This makes China's pharmaceutical companies no longer able to operate as before.

In this way, unscrupulous drug imitation will face huge market pressure and the living space will continue to be squeezed by foreign patented drugs.

However, technological innovation and the development of new drugs are an unattainable dream for most pharmaceutical companies. The research and development of new drugs is a high-profit and high-risk matter. It costs tens of millions to develop a new drug.

It is not surprising that US dollars or even hundreds of millions of dollars are spent. As early as the end of the last century in the United States, pharmaceutical companies spent tens of billions of dollars on new drug research and development every year, while China's investment over more than ten years may not even be able to equal the amount.

Such a large investment for one year, as well as the risk of R&D failure, and even if the R&D is successful, the intellectual property rights are not fully guaranteed, which makes these domestic pharmaceutical companies have no motivation to develop new drugs.

Therefore, in the future Chinese pharmaceutical market, the market share occupied by foreign pharmaceutical companies will become larger and larger, which means that it will become increasingly difficult for more and more state-owned pharmaceutical companies to operate, and some companies may even go bankrupt.

This result is definitely something the country is not willing to see. Fang Mingyuan also does not want such a result to occur. Although the domestic medical system determines the rise in medical expenses, the ex-factory price is cheaper, and the selling price will eventually be lower.

It can be cheaper. Some important drugs are monopolized by foreign pharmaceutical companies, causing the country to lose its pricing power. This is undoubtedly not conducive to the control of medical prices. Many of the Fang family's industries are in China, employing tens of thousands of workers. If

Saying that their medical care cannot be even basically guaranteed does not take advantage of the company's stable production.

Regarding this issue, he has actually considered it for a long time, but there are no conditions, and Angelina just sent the "pillow" for sleep, and of course he can't let it go. (To be continued...)